Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C27H26N2O3.CH4O3S |
| Molecular Weight | 522.613 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CS(O)(=O)=O.CC1=C(C(=O)C2=CC=CC3=C2C=CC=C3)C4=C5N1[C@H](CN6CCOCC6)COC5=CC=C4
InChI
InChIKey=FSGCSTPOPBJYSX-VEIFNGETSA-N
InChI=1S/C27H26N2O3.CH4O3S/c1-18-25(27(30)22-9-4-7-19-6-2-3-8-21(19)22)23-10-5-11-24-26(23)29(18)20(17-32-24)16-28-12-14-31-15-13-28;1-5(2,3)4/h2-11,20H,12-17H2,1H3;1H3,(H,2,3,4)/t20-;/m1./s1
WIN 55212-2 is the synthetic cannabimimetic compound. It is a potent aminoalkylindole cannabinoid receptor agonist. WIN 55,212-2 increases expression of anti-oxidant Cu/Zn SOD and is able to prevent inflammation induced by Aβ1-42 in cultured astrocytes. It exerts neuroprotective and anti-inflammatory actions against Aβ damage through both CB₁ and CB₂ receptors. WIN 55212-2 attenuates hyperalgesia and allodynia in a rat model of neuropathic pain. In the clinical trial, it was revealed that WIN 55212-2, applied topically, decreases the intraocular pressure of human glaucoma resistant to conventional therapies within the first 30 min.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL218 |
93.0 nM [Ki] | ||
Target ID: WP195 |
|||
Target ID: CHEMBL253 |
3.3 nM [Ki] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Preventing | Unknown Approved UseUnknown |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands. | 1996 Sep |
|
| Milk intake and survival in newborn cannabinoid CB1 receptor knockout mice: evidence for a "CB3" receptor. | 2003 Feb 7 |
|
| Neuropathic pain and the endocannabinoid system in the dorsal raphe: pharmacological treatment and interactions with the serotonergic system. | 2006 Oct |
Patents
Sample Use Guides
ChIP assays were performed to evaluate whether R(+)WIN 55,212-2 could affect the binding of the NF-kB subunit, p65, to the ICAM-1 and IL-8 promoters. 1321N1 astrocytoma were pre-treated with or without R(+)WIN 55,212-2 (20 uM) for 1 h prior to stimulation for a further 1 h in the absence or presence of IL-1 (10 ng/ml). p65 was absent at the promoters in unstimulated 1321N1 cells, but after 1-h stimulation with IL-1, p65 was detected at both promoters.
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
6604176
Created by
admin on Sat Dec 16 10:37:34 GMT 2023 , Edited by admin on Sat Dec 16 10:37:34 GMT 2023
|
PRIMARY | |||
|
WIN 55-212-2
Created by
admin on Sat Dec 16 10:37:34 GMT 2023 , Edited by admin on Sat Dec 16 10:37:34 GMT 2023
|
PRIMARY | |||
|
DBSALT002620
Created by
admin on Sat Dec 16 10:37:34 GMT 2023 , Edited by admin on Sat Dec 16 10:37:34 GMT 2023
|
PRIMARY | |||
|
2J851TP7VJ
Created by
admin on Sat Dec 16 10:37:34 GMT 2023 , Edited by admin on Sat Dec 16 10:37:34 GMT 2023
|
PRIMARY | |||
|
DTXSID50424974
Created by
admin on Sat Dec 16 10:37:34 GMT 2023 , Edited by admin on Sat Dec 16 10:37:34 GMT 2023
|
PRIMARY | |||
|
131543-23-2
Created by
admin on Sat Dec 16 10:37:34 GMT 2023 , Edited by admin on Sat Dec 16 10:37:34 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
PARENT (SALT/SOLVATE)
